ATHE | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 10%

Performance

5 Days

14.62%

1 Month

-9.15%

3 Months

-20.75%

6 Months

-21.78%

1 Year

-45.82%

2 Year

-74.81%

Key data

Stock price

$1.51

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$1.01 - $5.41

52 WEEK CHANGE

-$0.46

MARKET CAP

13.212 M

YIELD

N/A

SHARES OUTSTANDING

8.867 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$14,785

AVERAGE 30 VOLUME

$16,763

Company detail

CEO: Geoffrey Kempler
Region: US
Website: http://pranabio.com/
Employees: 10
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.

ATHE - Alterity Therapeutics Ltd - ADR